Teladoc Shorts Hold Firm as Analysts Lift Targets Post-Earnings

TDOC has now added 38% in a single week, yet the short book has barely moved, and analysts are still not calling it a buy.

The post-earnings momentum continued into this week. The stock closed at $8.89 on November 3, extending the 35% single-day surge from October 28 and adding a further 3% on Tuesday alone. The one-month gain is now 61%. That is a substantial recovery from the sub-$6 levels where insiders were selling in September. Critically, the stock has pushed above the previous mean analyst price target of $7.94, forcing the Street to respond.

The analyst response has been prompt but cautious. Following the earnings beat, Barclays raised its target from $7 to $9 while holding at Equal-Weight, UBS moved from $6.50 to $9 at Neutral, and JP Morgan lifted from $8 to $10 while keeping a Neutral rating. Oppenheimer, the only house with a constructive rating among the recent movers, went to $10 at Outperform. The pattern is clear: firms are acknowledging the beat by lifting their numbers, but very few are upgrading their ratings. The mean target now sits at $8.58, fractionally below the current price, which means the stock has effectively run through its consensus valuation in the week since results. The bull case centres on BetterHelp's insurance pivot showing early traction and Integrated Care again carrying the business. The bear case is harder to dismiss: FY26 revenue guidance still implies a 4.4% year-on-year decline at the midpoint, Q4 is guided to a 7.8% decline, and the BetterHelp DTC business fell 25% year-on-year in Q3. Insurance monetisation generated just $32 million, or 15% of BetterHelp revenue, in the quarter. EPS momentum ranks in the bottom 10% of the universe on both 30-day and 90-day measures, and analyst recommendation divergence sits in the fourth percentile, confirming that the Street's directional consensus is unusually tight, overwhelmingly neutral-to-negative.

Short sellers have not been shaken out. Short interest dipped slightly on the week, down about 1.6%, to 18% of the free float. That is a modest easing from the multi-year high set around October 29, but positions remain at historically elevated levels. The short book grew 13% over the past month and is still more than double where it was a year ago. Critically, the lending market creates no urgency for shorts to cover. Availability is 422%, meaning there are more than four shares available to borrow for every one already lent out, and the borrow cost is just 0.50%. There is no squeeze mechanism here. The ORTEX short score of 65.6 reflects a setup where positioning is high but the structural conditions for a forced unwind are absent. Options positioning is similarly undramatic: the put/call ratio at 0.44 is marginally below its 20-day average of 0.45, essentially flat, suggesting options traders are neither pressing hedges nor loading up on calls despite the rally.

One standout in the alt data is worth noting. Wikipedia views and ORTEX page views for Teladoc are running at a z-score of nearly 6.0 relative to the company's own prior 90-day history. That is an unusually sharp spike in retail attention, almost certainly driven by the earnings-day surge. The dataset has not been measured to lead the company's financial results, so it is colour rather than signal. But the attention spike does help explain the momentum character of the past week's trading.

Institutional ownership tells a subtler story. BlackRock added 1.6 million shares in the quarter to September 30, bringing its holding to 8.9% of shares. Dimensional Fund Advisors added 1.7 million shares to reach just under 5%. American Century added over 4 million shares in the same period. These are passive and quant buyers, not activist pressure, and no 13D filer is on the register. The insider picture is less encouraging: the 90-day net is negative, with the CEO and other senior officers selling in September at prices in the $6 range, well below current levels. Those sales were discretionary, not under 10b5-1 plans.

The next earnings print is not until February 22, 2027, leaving 110 days for the fundamental debate to play out. What to watch is whether short sellers begin to trim as the stock holds above the consensus price target, or whether the lack of analyst upgrades and the ongoing BetterHelp deterioration keep conviction on the short side intact.